Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allo-asc
- Development stage
- Phase 3
- Lead developer
- Anterogen
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional, Subcutaneous, Topical, Intraarticular, Intratendinous, Intramuscular
01
Overview
allo-asc is an allogeneic adipose-derived mesenchymal stem cell therapy developed by Anterogen. It is designed for cell replacement and tissue regeneration in various conditions. The product includes several formulations such as hydrogel sheets (ALLO-ASC-SHEET) and injectable forms (ALLO-ASC-TI), targeting diseases like diabetic foot ulcers and rectal fistula. Its mechanism of action involves the replacement of damaged or dysfunctional cells with healthy allogeneic mesenchymal stem cells to promote healing and tissue repair. The therapy has orphan drug designation for rectal fistula and has reached advanced clinical development stages in multiple indications including Crohn's disease and epidermolysis bullosa[1][2][3][5].
- Brand names
- AdipocellAdipoPlusCupistemQueencell
- Other names
- Allogeneic mesenchymal stem cells - AnterogenAllogeneic adipose stem cellsANTG-ASC
Beyond the preview
Go deeper on allo-asc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allo-asc.